Search Results - hanjoong+jo

4 Results Sort By:
Antisense Oligonucleotides Therapeutics Targeting Specific Tissues or Cells
Application Antisense oligonucleotide (ASO) therapies for the treatment of rare diseases and cancer. Key Benefits Novel approach to ASO therapeutics that potentially improve tissue/cell targeting capabilities. Increases the efficacy of ASOs while decrease off-target toxicity. Potential to treat a variety of genetic diseases such as cancer, blood...
Published: 8/22/2024   |   Inventor(s): Jiahui Zhang, Khalid Salaita, Hanjoong Jo
Keywords(s): Hematology/Blood Products, Oncology, Rare/Orphan Diseases
Category(s): TechPub Algolia > Therapeutics
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application Therapeutic use of miR-483 mimic for treating aortic valve clarification. Key Benefits MiR-483 or mimics of miR-483 could be used as a therapeutic. Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification. Market Summary Aortic stenosis (AS) is the most common type of heart...
Published: 8/22/2024   |   Inventor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
Keywords(s): Cardiovascular, Hospital and Surgery, Small Molecule
Category(s): TechPub Algolia > Drug Discovery, TechPub Algolia > Therapeutics
Immortalized Mouse Aortic Endothelial Cell Lines
Application Immortalized (using polyoma middle T-antigen) mouse aortic endothelial primary cell lines for studying vascular biology and pathophysiology, including cardiovascular research. Key Benefits Immortalized from mouse artery endothelial cells using polyoma middle T-antigen. Validated retention of primary endothelial markers and structural...
Published: 7/30/2024   |   Inventor(s): Hanjoong Jo, Chih-Wen Ni, Sandeep Kumar
Keywords(s): Cardiovascular, Cell Line
Category(s): TechPub Algolia > Research Tools
Inhibitors of MicroRNA-miR712/miR205 for the Treatment of Atherosclerosis and Other Vascular Conditions
Application Antisense oligonucleotide inhibitors of microRNA-miR712/miR205 to prevent or treat atherosclerosis and aortic aneurysm. Key Benefits 80% reduction on the expression of their microRNA targets. Reduces atheroma plaque formation in a mouse model of atherosclerosis. Provides potential non-surgical treatment for aortic aneurysm. Market...
Published: 7/30/2024   |   Inventor(s): Hanjoong Jo, Chanwoo Kim, Sandeep Kumar, Dong ju Son, Haiwei Qiu, Wakako Takabe
Keywords(s): Cardiovascular, Cell/Gene Therapy
Category(s): TechPub Algolia > Therapeutics